ASPIC

envie a um amigo share this

Phenotypic Intratumoral Heterogeneity of Endometrial Carcinomas


Cátia Silva MD 1,2, Ana S. Pires-Luís MD 3,4, Eduardo Rocha PhD 5, Carla Bartosch MD 2,3,4, José M. Lopes MD PhD 1,2,6

1Department of Pathology, Centro Hospitalar São João, Porto, Portugal;

2Department of Pathology and Oncology, Medical Faculty, University of Porto, Portugal;

3Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal;

Heterogeneidade Fenotípica Intratumoral dos Carcinomas do Endométrio

A heterogeneidade fenotípica intratumoral pode ter implicações no diagnóstico, terapêutica e prognóstico dos doentes oncológicos. A heterogeneidade intratumoral deve ser avaliada de forma objetiva para se averiguar o seu efeito na variabilidade clinico-patológica, agressividade, metastização e resposta à terapêutica dos tumores. No entanto, as metodologias e estratégias que têm sido utilizadas são muito diversificadas, incluindo métodos qualitativos e, recentemente, quantitativos.

Anti-tumor efficacy of new aromatase inhibitors in hormone-sensitive and resistant breast cancer cells

Breast cancer is the most common cause of cancer death in women, being 70%-80% of the tumors estrogen-receptor positive. One of the main therapeutic approaches applied is the use of aromatase inhibitors (AIs), since they decrease the synthesis of estrogens, which are necessary for the growth of this type of tumors. Although, despite its therapeutic success, the AIs used in the clinic induce some adverse effects, namely the occurrence of endocrine resistance.

Eficácia anti-tumoral de novos inibidores da aromatase em células de cancro da mama sensíveis e resistentes

O cancro de mama é a causa mais comum de morte por cancro em mulheres, sendo 70%-80% dos tumores recetor de estrogénio positivo. Uma das principais estratégias terapêuticas utilizadas é o uso de inibidores da aromatase (AIs), uma vez que diminuem a síntese de estrogénios necessários ao crescimento destes tumores. No entanto, apesar do seu sucesso terapêutico, os AIs utilizados na clínica induzem alguns efeitos adversos, nomeadamente o desenvolvimento de resistência endócrina.

4th EACR Conference A Matter of Life or Death: From Basic Cell Death Mechanisms to Novel Cancer Treatments

De Rode Hoed’s Great Hall, Amsterdam, Netherlands

 

01-03 February, 2018

 

See more informations here: https://www.eacr.org/conference/lifeordeath2018

4th EACR Conference A Matter of Life or Death: From Basic Cell Death Mechanisms to Novel Cancer Treatments

De Rode Hoed’s Great Hall, Amsterdam, Netherlands

 

01-03 February, 2018

 

See more informations here: https://www.eacr.org/conference/lifeordeath2018

Breast cancer heterogeneity and stromal alterations detected by LCM

This work was performed at Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA. We employed the technique of laser capture microdissection to obtain selected chosen cells without contamination of other cells that could interfere with final results of molecular analysis. Results confirmed that genetic alterations at specific loci of 9p occur earlier than discernable morphological or histopathological alterations and the presence of genetic alterations within morphologically normal breast tissue adjacent to carcinoma foci was also assessed.

Breast cancer heterogeneity and stromal alterations detected by LCM

This work was performed at Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA. We employed the technique of laser capture microdissection to obtain selected chosen cells without contamination of other cells that could interfere with final results of molecular analysis. Results confirmed that genetic alterations at specific loci of 9p occur earlier than discernable morphological or histopathological alterations and the presence of genetic alterations within morphologically normal breast tissue adjacent to carcinoma foci was also assessed.

Lung Cancer Centre of Excellence Conference 2017 03 - 05 December 2017, Manchester, UK

Lung Cancer Centre of Excellence Conference 2017 03 - 05 December 2017, Manchester, UK